http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Chi Hyuck Oh ) (검색결과 13 건)
- 무료
- 기관 내 무료
- 유료
-
-
( Jae-jun Shim ),( Tae-woong Choi ),( Chi Hyuck Oh ),( Soyung Park ),( Yu Jin Um ),( Byung-ho Kim ),( Ju-seog Lee ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Hepatocelluar carcinoma (HCC), the most common primary liver cancer, shows very heterogeneous gene expression patterns compared with intrahepatic cholangiocarcinoma (CC). Recent studies revealed a subset of HCCs showing CC - like features in histopathologic and genomic levels. We tried to identify these overlapping tumors and to characterize this unique phenotype of HCC in clinical perspective. Methods: Genomic data were downloaded from The Cancer Genome Atlas (TCGA) on human HCC (n=374) and intrahepatic CC (n=30). Using uniquely expressed genes between HCC and intrahepatic CC, total 52 tumors (13.9%) were predicted as “CC-like” phenotype among HCCs (BRB array tool, BCCP model, P<0.001, cut off probability = 0.1). We found uniquely expressed 1,122 genes (CC signature set) between CC-like HCCs and the other HCCs ((P<0.0001, four fold changes). Using the CC signature set, we identified CC-like subgroup in other independent HCC cohorts. Results: Gene expression patterns of CC-like HCCs were significantly correlated with poor prognosis. They shared gene expressions with hepatic progenitor-origin tumors suggesting their origin might be shared with intrahepatic CC. The CC-like HCC also showed more aggressive gene expression patterns. Finally, CC-like HCCs showed significantly shorter overall survival than non-CC type in validation cohorts. Conclusions: Unique phenotype of HCC exists sharing similar gene expressions with CC and its genetic features are correlated with aggressive tumor biology.
-
-
간암 국가암검진사업에 참여한 만성B형간염 환자에서 간암 발생률 조사
최인승 ( In Seung Choi ),오치혁 ( Chi Hyuck Oh ),박소영 ( So Young Park ),안성은 ( Sung Eun Ahn ),박성진 ( Seong Jin Park ),최현림 ( Hyun Rim Choi ),김병호 ( Byung-ho Kim ),심재준 ( Jae-jun Shim ) 대한간암학회 2017 대한간암학회지 Vol.17 No.2
Background/Aims: To optimize efficacy of National Liver Cancer Screening Program (NLCSP) for subjects with chronic hepatitis B (CHB), it is needed to know the incidence of liver cancer and its predisposing factors in the program. Methods: From January 2010 to December 2014, all the hepatitis B surface antigen (HBsAg) positive participants who received at least two or more abdominal ultrasonography under NLCSP were retrospectively enrolled in a single tertiary hospital. Annual incidence of primary liver cancer was calculated and related clinical factors were investigated. Results: During 5 years, 541 subjects were enrolled. Mean age was 53 years old and 292 subjects (54%) were receiving antiviral agents. Liver cirrhosis (LC) was diagnosed in 212 (39.2%). Mean follow-up time was 2.36 years and 15 hepatocellular carcinoma and 1 intrahepatic cholangiocarcinoma were diagnosed. Annual incidence of primary liver cancer was 9.8 per 1,000 patient year. Cumulative incidence at 1, 3, and 5 year was 0.6%, 2.6%, and 6.4%, respectively. In multivariate analyses, LC (hazard ratio [HR] 8.74, 95% confidence interval [CI] 1.97-38.71, P=0.024), age (HR 1.08, 95% CI 1.01-1.15, P=0.024) were significantly associated with cancer development. Conclusions: Despite of high rate of oral antiviral therapy, incidence of primary liver cancer is not low in CHB patients in Korea. Old age and presence of LC are independently associated with higher risk of cancer development during surveillance. This study could be used as baseline data for quality control of NLCSP. (J Liver Cancer 2017;17:136-143)
-
( Minah Jon ),( Jae-jun Shim ),( Shin Ju Oh ),( In Zoo Choi ),( Chi Hyuck Oh ),( Byung-ho Kim ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Abdominal ultrasonography (US) and alpha-fetoprotein (AFP) testing are components of the nationwide liver cancer surveillance program in South Korea. However, whether this surveillance strategy improves the detection rate of single and small (< 2 cm) hepatocellular carcinoma (HCC) in high-risk groups is unclear. Methods: We investigated the detection process and the clini cal features of small HCC in a single healthcare center in South Korea from 2006 to 2015. Surveillance comprised US and AFP screening every 6 to 12 months; computed tomography (CT) was performed in place of US at the discretion of the clinician. Results: During the study period, 916 patients were newly di agnosed with HCC, of whom 91 (9.9%) had a small HCC. The proportion of small HCC was 9.5% from 2006 to 2010 and 10.4% from 2011 to 2015 (P=0.677). The proportion of small HCC did not increase significantly during the 10-year period (Figure, P for trend = 0.297). The majority of patients with small HCC were detected by surveillance (N=57, 62.6%), followed by screening (N=14, 15.4%), and incidentally (N=20, 22.0%). Between 2006 to 2010 and 2011 to 2015, 65.2% and 60.0%, respectively, of small HCCs were detected by surveillance (P for trend=0.609). CT scan detected the largest proportion of small HCCs (45.1%), followed by US (40.7%), AFP elevation (12.1%), and magnetic resonance imaging (MRI) (2.2%). The overall 1-, 3-, and 5-year survival rates of treated patients were 96.0%, 84.6%, and 79.8%, respectively. Transarterial chemoemboli zation (TACE) was the most commonly performed initial treat ment (N=46, 50.5%), due to an unfavorable tumor location or decreased liver function. Surgical resection and ablation were performed in 11 (12.1%) and 26 (28.6%) patients, respectively. However, there was no significant difference in the overall sur vival rate between patients who underwent surgical resection and those subjected to surgical ablation (P=0.295 by log-rank test). Conclusions: Surveillance plays a major role in early detection of HCC. However, the current surveillance strategy is inade quate for the detection of small HCC in cirrhotic patients; more effective and practical surveillance strategies are needed.
-
( Jae-jun Shim ),( Tae-woong Choi ),( Chi Hyuck Oh ),( Soyung Park ),( Yu Jin Um ),( Byung-ho Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Asians have a higher risk of hepatocellular carcinoma (HCC) development than Caucasians. However, the risk of HCC was not compared among Asian countries. Methods: Population data, prevalence of chronic hepatitis B or C, and annual number of hepatitis B virus (HBV) - or hepatitis C virus (HCV) - related HCC cases (40-79 years of age) were acquired from publicly available data. The incidence of HCC among patients with chronic viral hepatitis were calculated according to age groups Results: The risk of HBV-related HCC in Koreans was more than twice that in Taiwanese. The annual incidence of HCC was 947 per 100,000 HBsAg-positive patients in 2005. This was equivalent to 1 HCC occurrence for every 106 patients with chronic hepatitis B (CHB) per year. From 2005 to 2011, the annual incidence in Korea did not change; the average was 906 per 100,000 persons (0.91%/year). In Taiwan, the incidence was 378 per 100,000 patients per year in 2002. One HCC was diagnosed for every 265 patients with CHB. The incidence among young adults (40-49 years of age) was compared because most HCCs that develop in individuals in this age group are HBV-related. The incidence was 495 and 155 per 100,000 patients with CHB in Korea and Taiwan, respectively. The mortality rate due to HBV-related HCC was 434 and 136 per 100,000 patients in Korea and Taiwan, respectively. However, the incidence of HCV-related HCC was similar in the two countries; 570 and 519 per 100,000 patients with chronic hepatitis C in Korea and Taiwan, respectively. Conclusions: The risk of HCC is much higher in Korean patients with CHB than in Taiwanese, however the risk is similar among chronic hepatitis C.
-
( Jae-jun Shim ),( Tae-woong Choi ),( Chi Hyuck Oh ),( Soyung Park ),( Yu Jin Um ),( Byung-ho Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Risk for hepatocellular carcinoma (HCC) development decreases but not completely disappears by long-term use of nucleos(t)ide analogues in patients with chronic hepatitis B (CHB). The aim of this study was to investigate incidence of HCC in CHB patients under antiviral therapy and to reveal clinical parameters related with HCC development. Methods: We collected clinical data retrospectively from 364 consecutive naive patients with CHB (40 to 70 years of age), who received entecavir for more than 6 months from January 1, 2007 to December 31, 2013. Incidence of HCC according to various clinical parameters including presence of liver cirrhosis was estimated. Kaplan-Meyer analysis and a multivariable Cox proportional hazards model were used for analysis. Results: Median age of patients was 51 years. Among the patients, 228 (62.6%) had liver cirrhosis, and 338 (92.9%) achieved complete virological response. Median ALT was 74 U/L and serum HBV DNA level was 6.79 log10 copies/mL. Total observation time of all patients was 1,293 years (mean 3.6 years per patient). During the period, 46 patients (12.6%) developed HCC. In univariate analysis, presence of liver cirrhosis, old age more than 50 years, low albumin (< 3.8 g/dL), and low platelet counts (< 120,000/mm3) were associated with higher risk of HCC development. In multivariate analysis, only presence of liver cirrhosis at the starting time of antiviral therapy was significantly associated with higher risk of HCC development (hazard ratio 6.9; 95% confidence interval [CI], 1.6-30.8) Annual incidence of HCC between cirrhotic and non-cirrhotic patients was 5.6% and 0.4% per year, respectively (P<0.001 by Log Rank test). Conclusions: Once CHB progressed to liver cirrhosis, risk for HCC development is unacceptably high despite of long-term antiviral therapy. We should consider earlier initiation of antiviral therapy before too late.
-
( Jae-jun Shim ),( Tae-woong Choi ),( Chi Hyuck Oh ),( Soyung Park ),( Yu Jin Um ),( Byung-ho Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: REACH-B is a simple scoring system to predict HCC risk in non-cirrhotic patients with chronic hepatitis B (CHB). However, it is not known whether the model can accurately predict HCC risk in patients under long-term antiviral therapy. This study aimed to validate modified REACH-B model to predict HCC risk in patients receiving entecavir. Methods: From 2007 to 2013, total 136 naive patients (40 to 70 years of age) with CHB who had been treated for more than 6 months were retrospectively collected. None of them had liver cirrhosis. We hypothesized that HCC risk remains unchanged during the first two year and decrease thereafter. Two-year HCC risk was calculated from baseline data before antiviral therapy and the remaining 3-year risk was calculated from improved parameters following 2-year antiviral therapy. Results: Median age of patients was 49 years. HBeAg positive CHB were 77 (56.6%). Median ALT was 102 U/L. Baseline serum HBV DNA level was 7.51 log10 copies/mL. The patients were observed for total 507.5 years. The 5-year HCC risk of non-treated patients was predicted as 7.36%. It was equivalent to annual incidence of 1,472 per 100,000 persons with CHB. If they were treated, the 5-year HCC risk was dramatically decreased to 2.48%. Annual incidence was 496 per 100,000 persons with CHB. During actual follow-up period, two patients developed HCC. The incidence was 394 per 100,000 person year and 5-year cumulative incidence was estimated to 1.97%. There was no difference between predicted and actual incidence of HCC (P = 0.907 by Log Rank test). Actual and predicted incidence following antiviral therapy decreased as compared with that of non-treatment, however, the difference did not meet statistically significance (P = 0.176 by Log Rank test). Conclusions: Modified REACH-B model can predict 5-year risk of HCC in patients with CHB under long-term antiviral therapy.
-
( Jae-jun Shim ),( Tae-woong Choi ),( Chi Hyuck Oh ),( Soyung Park ),( Yu Jin Um ),( Byung-ho Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: To optimize efficacy of National Liver Cancer Screening Program (NLCSP) for subjects with hepatitis B surface antigen (HBsAg) positive, it is crucial to know the incidence of hepatocellular carcinoma (HCC) development and its predisposing factors in the program. Methods: From January 2010 to December 2014, all the HBsAg positive participants who received at least two or more abdominal ultrasonography under NLCSP were retrospectively enrolled in a single tertiary hospital. Annual incidence of HBV-related HCC was calculated and related clinical factors were investigated. Results: During 5 years, 541 subjects were enrolled. Mean age was 53 years old and 310 (57.3%) were male. Most subjects (86.5%) were patients of current hospital. Two hundred ninety two subjects (54%) were receiving antiviral agents at the moment. Liver cirrhosis (LC) was diagnosed in 212 (39.2%) by ultrasonography or upper endoscopy. Esophageal varices were found in 63 (14.8%). Total bilirubin, albumin, platelets, and aminotransferases were normal in most subjects. HBV DNA were less than 2,000 IU/mL in 356 subjects (79.6%). Mean follow-up time was 2.4 years and 16 new HCCs were diagnosed. Annual incidence of HBV-related HCCs were 980 per 100,000 patient year (1% per year). Subjects more than 60 years old (2.2% per year) had higher risk of HCC development than those under 60 years (0.6% per year, P<0.005 by Log Rank test). Presence of LC (2.2% per year) also showed higher risk of HCC than LC-free state (0.2% per year, P<0.0001 by Log Rank test). In cirrhotic patients older than 60 years old, the incidence increased up to 3.8% per year. Conclusions: Despite of high rate of antiviral therapy, incidence of HBV-related HCC is not low in participant of NLCSP in Korea. Old age and presence of liver cirrhosis are associated with higher risk of HCC development.
-
S-131 Incidence of Hepatocellular carcinoma in korean screenee with chronic hepatitis B
( Jung Rock Moon ),( Jae-jun Shim ),( Tae-woong Choi ),( Chi Hyuck Oh ),( Soyung Park ),( Yu Jin Um ),( Byung-ho Kim ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Background: To optimize efficacy of National Liver Cancer Screening Program (NLCSP) for subjects with HBsAg positive, it is crucial to know the incidence of HCC and its predisposing factors in the program. Methods: From January 2010 to December 2014, all the HBsAg positive participants who received at least two or more abdominal ultrasonography under NLCSP were retrospectively enrolled in a single tertiary hospital. Annual incidence of HBV-related HCC was calculated and related clinical factors were investigated. Results: During 5 years, 541 subjects were enrolled. Liver cirrhosis was diagnosed in 212 (39.2%) by ultrasonography or upper endoscopy. Esophageal varices were found in 63 (14.8%). Total bilirubin, albumin, platelets, and aminotransferases were normal in most subjects. HBV DNA were less than 2,000 IU/mL in 356 subjects (79.6%). Mean follow-up time was 2.4 years and 16 new HCCs were diagnosed. Annual incidence of HBV-related HCCs were 980 per 100,000 patient year (1% per year). Subjects more than 60 years old (2.2% per year) had higher risk of HCC development than those under 60 years (0.6% per year, p<0.005). Presence of LC (2.2% per year) also showed higher risk of HCC than LC-free state (0.2% per year, p<0.0001). In cirrhotic patients over 60 years old, the incidence increased up to 3.8% per year.Conclusions: Despite of high rate of antiviral therapy, incidence of HBV-related HCC is not low in participant of NLCSP in Korea. Old age and presence of LC are associated with higher risk of HCC development.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
